Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06822426 · ClinicalTrials.gov registry record · Phase 3
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
A Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI), sponsored by CorMedix.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 15
- Study locations
NCT06822426 is a Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI) that is actively recruiting participants, run by CorMedix. The registered enrollment target is 200 participants. The trial reports 15 study locations across 15 states.
The verdict
NCT06822426, a Phase 3 study of Central Line Associated Blood Stream Infections (CLABSI), is actively recruiting participants, sponsored by CorMedix.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Conditions Studied
Interventions
- DRUG Heparin
- DRUG (taurolidine and heparin) catheter lock solution
Study Locations (15)
California
- University of California Los Angeles - Los Angeles
District of Columbia
- MedStar Health Research Institute - Washington D.C.
Florida
- Bioresearch Partner - Doral
Georgia
- Emory University Hospital - GCRC - Atlanta
Iowa
- University of Iowa Health Care - Iowa City
Maryland
- Johns Hopkins Clinical Research Unit - Baltimore
Minnesota
- Mayo Clinic - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06822426
The ClinicalTrials.gov registry entry for NCT06822426 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CorMedix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Line Associated Blood Stream Infections (CLABSI) appearing as the primary indexed condition, and to 2 interventions - of which Heparin is the first listed.
NCT06822426 reports 15 study locations spanning 15 distinct geographic areas - top geographies include California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT06822426 about?
NCT06822426 is a clinical study titled "Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)". This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
What is the current status of trial NCT06822426?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-05-14. Estimated completion is 2027-01.
What conditions does trial NCT06822426 study?
This clinical trial studies the following conditions: Central Line Associated Blood Stream Infections (CLABSI).
What interventions are being tested in trial NCT06822426?
The interventions under investigation include: Heparin (DRUG), (taurolidine and heparin) catheter lock solution (DRUG).
Who is sponsoring clinical trial NCT06822426?
This trial is sponsored by CorMedix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06822426 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Line Associated Blood Stream Infections (CLABSI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.